ABSTRACT
Cross-resistance among Candida albicans isolates from the oropharynges of human immunodeficiency virus-infected patients (n = 16) and environmental yeast strains of various species (n = 54) to medical and agricultural azole drugs was observed. Precautions against the unnecessary widespread use of azoles in the environment and human medicine are strongly recommended to prevent patients from acquiring azole-resistant yeasts.
Subject(s)
Antifungal Agents/pharmacology , Azoles/pharmacology , Candida albicans/drug effects , Drug Resistance, Fungal , Fungicides, Industrial/pharmacology , Oropharynx/microbiology , Vitis/microbiology , AIDS-Related Opportunistic Infections/microbiology , Candida albicans/classification , Candida albicans/isolation & purification , Candidiasis, Oral/drug therapy , Candidiasis, Oral/microbiology , Environmental Microbiology , Germany , HIV Infections/complications , HIV-1 , Humans , Microbial Sensitivity TestsABSTRACT
Effects of voriconazole combined with micafungin against 101 isolates of Candida spp. and 100 isolates of filamentous fungi have been evaluated by in vitro checkerboard analysis. The combination was indifferent for 97% of the Candida isolates and synergistic for 64% of the filamentous fungi (79% for Aspergillus fumigatus).
